Ultragenyx Pharmaceutical Inc (RARE)

NASDAQHealth CareBiotechnologySnapshot 2026-09-09

$14.31-3.83%

Close 2026-09-09 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Intact: The reason to own it still holds.

The bull case

Ultragenyx aims for Dojolvi sales between $100M and $110M in 2026. The company is cutting costs with a 10% workforce reduction. Analysts expect revenue to grow about 30% next year. New gene therapy approvals and partnerships could boost future sales.

The bear case

Ultragenyx is still losing money and missed recent earnings. Legal and regulatory challenges could delay product launches. Revenue guidance for 2026 is much lower than 2025 actuals, signaling growth risks.

What's priced in

The stock price is about 43% below our valuation level and 45% above the Street median. Analysts expect nearly 30% revenue growth next year. Our view aligns with this growth but recognizes ongoing losses and execution risks.

What has to stay true

Dojolvi revenue between $100M and $110M in 2026Intact
Revenue Growthprimary$100M to $110M · FY26 (guidance)
Breaks if: Dojolvi revenue falls below $100M in FY26
Are they delivering?On Track this quarter· 1 tracked commitment
- Dojolvi revenue guidance of $100M to $110MGrowth
  Achieve full year 2026 Dojolvi revenue guidance in the range of $100 million to $110 million.
  On Track

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-09· Version 1· Status: Intact· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

RARE is navigating a challenging landscape with mixed signals for its long-term thesis.

What kind of bet this is

This investment represents a turnaround story in the healthcare sector. RARE is currently loss-making and has a volatile management track record, but it is working towards achieving its revenue goals amidst a supportive sector backdrop.

What's priced into Ultragenyx Pharmaceutical Inc (RARE)

The market seems to have priced in a low level of fragility, with RARE being seen as cheap compared to its peers. However, there is an expectations gap, indicating that the market may not fully believe in the company's ability to meet its revenue guidance.

What the fundamentals likely do

Management is on track to meet its revenue guidance for 2026, with recent growth in total revenue and Dojolvi sales. However, the mixed results in controlling operating expenses and the overall risk of missing earnings could create volatility in the near term.

What Ultragenyx Pharmaceutical Inc (RARE) hinges on

The thesis hinges on RARE's ability to maintain its revenue guidance and manage costs effectively. Additionally, the performance of sector bellwethers and broader economic indicators, like job growth, will be crucial in shaping investor sentiment.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Yes, our read has weakened. The recent sharp drop in RARE's stock price suggests a market repricing. This follows the failure of a late-stage trial for a key drug, which undermines revenue potential. However, the company did report a strong earnings beat, with revenue exceeding forecasts.

as of 2026-09-09

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.